WHAT IS EARLY START AND WHY IT SHOULD NOT BE SYSTEMATIC? Christian Com be, Bordeaux, France
|
|
- Buddy Boyd
- 6 years ago
- Views:
Transcription
1 WHAT IS EARLY START AND WHY IT SHOULD NOT BE SYSTEMATIC? Christian Com be, Bordeaux, France Chair: Mustafa Arici, Ankara, Turkey Bernard Canaud, Montpellier, France Prof Christian Combe Servic e de N éphrologie T rans plantation Dialys e Hopital P ellegrin C entre H os pitalier U nivers itaire de Bordeaux Bordeaux, Franc e Slide 1 Thank you Bernard. So I m supposed to speak about early start and m y friend Charlie Tom son will speak of late start but unfortunately, usually we agree and Jam es Tattersall will say what good dialysis is. So we have 10 m inutes to review what early start is. So I will be very brief. Slide 2
2 Early start is initiation of dialysis at an egfr of m ore than 10 m l/m in by the MDRD equation. So that s a definition that I take for m yself, it s from Rosansky and I would add that there is no clinical or biological need to com m ence dialysis. Slide 3 So, early start is a tendency in m any countries. For instance, in the US-RDS now m ore than 50% of patients begin dialysis at a GFR higher than 10 m l/m in. The European data are the sam e. Slide 4
3 If we look at the French data, we can see that the proportion of patients who begin dialysis at m ore than 10 m l/m in is increasing and m ean GFR diuresis start is increasing. The scale here is quite extended. Slide 5 So if people begin dialysis at high GFRs, can we m easure accurately renal function in CKD stage 5? This has been addressed in a nice study from the NECOSAD study. Slide 6
4 If we look at the MDRD equation in CKD stage 5 patients from Holland then we can see that there is a wide m argin of variation, especially at the tim e when decision is taken, that is you cannot rely entirely on this. Slide 7 Another point is that if you look at m uscle m ass, which is a determ inant of the production of creatinine, there is no relationship between m uscle m ass and m easured creatinine clearance. But if you look at the relationship between m uscle m ass and egfr, then the patients who have the lower m uscle m ass have the highest egfrs. That is in people who have low m uscle m ass, who are undernourished, then you m ay begin dialysis earlier because you have a m isestim ation of GFR. Slide 8
5 So the next question is: could we anticipate the decline of renal function, if we plan dialysis can we predict the evolution of renal function in CKD patients of stages 4 and 5? Slide 9 From this study from the group of Nancy, France you can see that in som e patients the decline in GFR is really linear. So in these patients you can predict that dialysis will be in x days or m onths. Slide 10
6 But in m any patients you have fluctuations which m ay be probably related to fluctuations in the hydration status of the patients and you cannot predict, so therefore you cannot say to a patient you will be on dialysis within 3 m onths, let s begin now. Slide 11 The next question is: is early start of dialysis associated with better survival? Slide 12
7 So the basic idea is that when renal function is altered, there is an increase in m ortality and specifically in cardiovascular m ortality. This has been extensively shown; in this aggregation of cohort studies you have m ore than 1 m illion patients. Slide 13 So the next step is to say that if you have a lower creatinine clearance, this has been shown for instance in the CANUSA study, the lower the creatinine clearance the poorer the survival of the patients who are beginning peritoneal dialysis. So this is true and intuitively you can say that with a creatinine clearance of zero you will have zero survivals. Slide 14
8 But the problem is that in this study as in others the type of creatinine clearance that you can achieve is not equivalent to having residual renal function and to having creatinine clearance achieved by peritoneal dialysis. Slide 15 So the concept of early dialysis start was m ade m ainly on this type of studies. So we needed as nephrologists random ised controlled studies. This has been done in the South hem isphere by the colleagues of Australia and New Zealand. They have designed the IDEAL study, Initiating Dialysis Early And Late. The design of their study was to have patients with early start m l/m in versus late start 5-7 m l/m in. Slide 16
9 Actually what they have achieved is a different of 2.2 m l/m in that is 12 versus 9.8 m l/m in. Not a very significant difference with a delay of dialysis which was significant of 7 m onths in the late start group. There is absolutely no difference between the early start and the late start group. So from this random ised controlled study, in which probably we have a lack of clinically significant power, there is no difference in m ortality in late versus early start but m any patients from the late start had to begin dialysis earlier. Slide 17 In m any registries, this is an exam ple from the French Registry, the beginning of dialysis at lower GFR is associated with a better survival. The patients who begin dialysis at high GFRs are usually the elderly that is the patients who have lost m uscle m ass, who produce less creatinine and they are the patients in whom egfr is not reliable. Slide 18
10 So is early start of dialysis associated with better outcom es in the elderly? Slide 19 So this is a study which was published in the New England Journal of Medicine 3 years ago in patients who were in nursing hom es and they had becom e dialysis at a egfr of 10.7 m l/m in. What happened to them? Many of them died and m any of them declined in term s of functional status. So in this study there was absolutely no evidence for an im provem ent in the functional status of these patients. Slide 20
11 However, we have to prepare dialysis. This is from patients from Brazil with different age groups and you have the outcom e of patients: they can survive without renal replacem ent therapy, they can be treated with renal replacem ent therapy or they can die without renal replacem ent therapy. So it s worth preparing dialysis even if you re not convinced of early start as I am. Slide 21 So to sum m arise, early start of dialysis relies on estim ations of renal functions linked in part to nutrition. It has not been shown in random ised controlled trials or observational studies to im prove outcom es in term s of m ortality, m orbidity, nutrition, quality of life, health expenditures. So it can be indicated in som e circum stances, for instance, preparation for transplant especially and thinking of polycystic kidney disease. It can be indicated when there are associated com orbidities, oedem a, urem ic syndrom e or whatever but in any case it should not be system atic but ESRD should be anticipated. Slide 22
12 I thank you for your attention and I think m y friend Charlie will answer this question: is late start better?
LONG DIALYSIS SESSIONS (DAILY, NOCTURNAL ETC) Ercan Ok, Izm ir, Turkey. Chair: Mustafa Arici, Ankara, Turkey Bernard Canaud, Montpellier, France
LONG DIALYSIS SESSIONS (DAILY, NOCTURNAL ETC) Ercan Ok, Izm ir, Turkey Chair: Mustafa Arici, Ankara, Turkey Bernard Canaud, Montpellier, France Prof Ercan Ok Divis ion of N ephrology E ge U nivers ity
More informationProf. Rosanna Coppo Director of the Nephrology, Dialysis and Transplantation Department Regina Margherita Hospital Turin, Italy. Slide 1.
ROLE OF PATHOLOGY AND CLINICAL FEATURES IN PREDICTING PROGRESSION OF IGA NEPHROPATHY: RESULTS FROM THE ERA-EDTA RESEARCH VALIGA Rosanna Coppo, Turin, Italy Chairs: François Berthoux, Saint-Etienne, France
More informationWHEN (AND WHEN NOT) TO START DIALYSIS. Shahid Chandna, Ken Farrington
WHEN (AND WHEN NOT) TO START DIALYSIS Shahid Chandna, Ken Farrington Changing Perspectives Beta blockers 1980s Contraindicated in heart failure Now mainstay of therapy HRT 1990s must Now only if you have
More informationAcknowledgements. National Kidney Foundation of Connecticut Mark Perazella. Co-PI Slowing the progression of chronic kidney disease to ESRD
A Practical Approach to Chronic Kidney Disease Management for the Primary Care Practioner: A web-site sponsored by the National Kidney Foundation of Connecticut Robert Reilly, M.D. Acknowledgements National
More informationCKD Prevention Program Protocol
CKD Prevention Program Protocol Taiwan Pathway as an example I. Understanding problems and situations of ESRD/CKD in Taiwan 1. Understanding the ESRD/CKD Burden 1) National Dialysis Registry since 1987
More informationThe Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.1.55 The Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival Seoung Gu Kim 1 and Nam Ho Kim 2 Department of Internal Medicine,
More informationNarender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York
Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York 4th International Conference on Nephrology & Therapeutics September 14, 2015 Baltimore,
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Level of renal function at which to initiate dialysis GUIDELINES
Level of renal function at which to initiate dialysis Date written: September 2004 Final submission: February 2005 GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR
More informationCKD and risk management : NICE guideline
CKD and risk management : NICE guideline 2008-2014 Shahed Ahmed Consultant Nephrologist shahed.ahmed@rlbuht.nhs.uk Key points : Changing parameters of CKD and NICE guidance CKD and age related change of
More informationProf. David Wheeler Centre for Nephrology Royal Free Campus University College London Medical School London, UK. Slide 1
LDL-CHOLESTEROL AND CV RISK IN CKD: EPIDEMIOLOGY VS. CLINICAL TRIALS David Wheeler, London, UK Chairs: Maurice Laville, Lyon, France Erling B. Pedersen, Holstebro, Denmark Prof. David Wheeler Centre for
More informationDialysis versus Supportive Care
Dialysis versus Supportive Care with a focus on the initial pathway in the elderly DNT Workshop. Glenelg, February 2017 Background: A better title would be dialysis v non-dialysis! For this discussion:
More informationProf. Andrzej Wiecek Department of Nephrology, Endocrinology and Metabolic Diseases Medical University of Silesia Katowice, Poland.
What could be the role of renal denervation in chronic kidney disease? Andrzej Wiecek, Katowice, Poland Chairs: Peter J. Blankestijn, Utrecht, The Netherlands Jonathan Moss, Glasgow, UK Prof. Andrzej Wiecek
More informationDifference in practical dialysis therapy between East Asia and US/EU
Difference in practical dialysis therapy between East Asia and US/EU Jer-Ming Chang. M.D., Ph.D. 1 Professor, Attending physician, Kaohsiung Medical University Hospital; 2 Secretary General, Taiwan Society
More informationCHAPTER 9. End Stage Kidney Disease in Aotearoa/New Zealand
CHAPTER 9 End Stage Kidney Disease in Aotearoa/New Zealand ANZDATA gratefully acknowledges the patients and their families and the clinicians who provided data, and the contributions of the Aotearoa/New
More informationUnited States Renal Data System (USRDS) International Data Collection Form
United States Renal Data System (USRDS) International Data Collection Form This form is designed to solicit information on the population of End-Stage Renal Disease (ESRD) patients in your country who
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Monitoring patients on peritoneal dialysis GUIDELINES
Date written: August 2004 Final submission: July 2005 Monitoring patients on peritoneal dialysis GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationThe Pursuit of Prevention of Renal failure in an imperfect world-is it possible in the 21 st century?
The Pursuit of Prevention of Renal failure in an imperfect world-is it possible in the 21 st century? By: Baskar, WDHB, Renal Service Auckland New Zealand Presented at : 4 th International Conference on
More informationChronic renal disease in the elderly: are all pigs to be considered equal?
Chronic renal disease in the elderly: are all pigs to be considered equal? W. Van Biesen, Ghent University Hospital Elwood et al, cjasn, 2013 Elderly and CKD: a thematic synthesis Overview CKD in the
More informationKrediet slide di 18
1 di 18 Assessment of fluid status in PD patients Raymond T. Krediet, Amsterdam, Netherlands Chairs:Walther H. Boer, Utrecht, The Netherlands F. Fevzi Ersoy, Antalya, Turkey Prof. Raymond T. Krediet DDivision
More informationChronic Kidney Disease: Optimal and Coordinated Management
Chronic Kidney Disease: Optimal and Coordinated Management Michael Copland, MD, FRCPC Presented at University of British Columbia s 42nd Annual Post Graduate Review in Family Medicine Conference, Vancouver,
More informationConcept and General Objectives of the Conference: Prognosis Matters. Andrew S. Levey, MD Tufts Medical Center Boston, MA
Concept and General Objectives of the Conference: Prognosis Matters Andrew S. Levey, MD Tufts Medical Center Boston, MA General Objectives Topics to discuss What are the key outcomes of CKD? What progress
More informationA New Approach for Evaluating Renal Function and Predicting Risk. William McClellan, MD, MPH Emory University Atlanta
A New Approach for Evaluating Renal Function and Predicting Risk William McClellan, MD, MPH Emory University Atlanta Goals Understand the limitations and uses of creatinine based measures of kidney function
More informationAcceptance onto dialysis guidelines: St George Hospital
Acceptance onto dialysis guidelines: St George Hospital The following information is a guideline to support clinicians in decision making regarding acceptance onto dialysis. A review of international guidelines
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationUpdate on HIV-Related Kidney Diseases. Agenda
Update on HIV-Related Kidney Diseases ANDY CHOI THE MEDICAL MANAGEMENT OF HIV/AIDS DECEMBER 15, 2006 Agenda 1. EPIDEMIOLOGY: A) END STAGE RENAL DISEASE (ESRD) B) CHRONIC KIDNEY DISEASE (CKD) 2. HIV-ASSOCIATED
More informationANAEMIA MANAGEMENT: THE KDIGO RECOMMENDATIONS Patrick S. Parfrey, St. John s, Canada
ANAEMIA MANAGEMENT: THE KDIGO RECOMMENDATIONS Patrick S. Parfrey, St. John s, Canada Chair: Kai- Uwe Eckardt, Erlangen, Germany Pierre- Yves Martin, Geneva, Switzerland Prof. Patrick S. Parfrey Division
More informationThe National Quality Standards for Chronic Kidney Disease
The National Quality Standards for Chronic Kidney Disease Dr Robert Lewis Chief of Service, Wessex Kidney Centre, Portsmouth Specialist Committee Member Quality Standard for Chronic Kidney Disease, NICE
More informationZhao Y Y et al. Ann Intern Med 2012;156:
Zhao Y Y et al. Ann Intern Med 2012;156:560-569 Introduction Fibrates are commonly prescribed to treat dyslipidemia An increase in serum creatinine level after use has been observed in randomized, placebocontrolled
More informationProf. Michel Jadoul Cliniques universitaires St-Luc Université Catholique de Louvain Brussels, Belgium. Slide 1
Phosphate and cardiovascular disease beyond CKD: is phosphate a new cholesterol? Michel Jadoul, Brussels, Belgium Chairs: Pablo Urena Torres, Saint-Ouen, France Carmine Zoccali, Reggio Calabria, Italy
More informationEconomic evaluation of end stage renal disease treatment Ardine de Wit G, Ramsteijn P G, de Charro F T
Economic evaluation of end stage renal disease treatment Ardine de Wit G, Ramsteijn P G, de Charro F T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationCOGNITIVE ALTERATIONS IN CHRONIC KIDNEY DISEASE K K L E E
COGNITIVE ALTERATIONS IN CHRONIC KIDNEY DISEASE K K L E E Attention Problem Solving Language Cognitive Domains Decision Making Memory Reasoning The Cardiovascular Health Cognition Study shows higher S
More informationThe Health Problem: Guidelines: NHS Priority:
PRIORITY BRIEFING The purpose of this briefing paper is to aid Stakeholders in prioritising topics to be taken further by PenCLAHRC as the basis for a specific evaluation or implementation research project.
More informationMETABOLISM AND NUTRITION WITH PD OBESITY. Rajnish Mehrotra Harborview Medical Center University of Washington, Seattle
METABOLISM AND NUTRITION WITH PD OBESITY Rajnish Mehrotra Harborview Medical Center University of Washington, Seattle 1 Body Size in Patients New to Dialysis United States Body Mass Index, kg/m2 33 31
More informationREVISITING THE PHARMACOKINETICS IN PATIENTS
REVISITING THE PHARMACOKINETICS IN PATIENTS WITH IMPAIRED RENAL FUNCTION IN THE LIGHT OF THE LATEST FDA AND EMA GUIDELINES 3 RD CONFERENCE OF EUROPEAN PHARMACOLOGICAL SOCIETIES EUROPEAN COMPETITIVENESS
More informationCKD Conservative care and preparation for dialysis Dr Anirudh Rao Registrar, UK Renal Registry. UK Renal Registry 2013 Annual Audit Meeting
CKD Conservative care and preparation for dialysis Dr Anirudh Rao Registrar, UK Renal Registry UK Renal Registry 2013 Annual Audit Meeting Scope of the talk Background CK MAPPS EQUAL My Research Future
More informationTechnology appraisal guidance Published: 28 October 2015 nice.org.uk/guidance/ta358
Tolvaptan for treating autosomal dominant polycystic kidney disease Technology appraisal guidance Published: 28 October 2015 nice.org.uk/guidance/ta358 NICE 2017. All rights reserved. Subject to Notice
More informationSummary. 20 May 2014 EMA/CHMP/SAWP/298348/2014 Procedure No.: EMEA/H/SAB/037/1/Q/2013/SME Product Development Scientific Support Department
20 May 2014 EMA/CHMP/SAWP/298348/2014 Procedure No.: EMEA/H/SAB/037/1/Q/2013/SME Product Development Scientific Support Department evaluating patients with Autosomal Dominant Polycystic Kidney Disease
More informationFIRST RENAL REPLACEMENT
FIRST RENAL REPLACEMENT THERAPY SELECTION IN DIABETIC PATIENTS Dr Cécile Couchoud (REIN registry, France) Davide Bolignano (ERBP, Italy) European Renal Best Practice Prof. Wim Van Biesen Chairman of ERBP
More informationMeasurement and Estimation of renal function. Professeur Pierre Delanaye Université de Liège CHU Sart Tilman BELGIQUE
Measurement and Estimation of renal function Professeur Pierre Delanaye Université de Liège CHU Sart Tilman BELGIQUE 1 2 How to estimate GFR? How to measure GFR? How to estimate GFR? How to measure GFR?
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationwe usually use PAH - a substance called para-amino-hippouric acid to measure Clearance because it has the following characteristics :
مرحبا.. Last Lecture we where talking about How to measure Renal Plasma Flow (aka RPF), Recall that we used a substrance that is 100 % CLEARED from the plasma ONCE it enter the kidney. Today s lecture
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2011 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /200 pts 1 Question Set I (True or
More informationProf. Armando Torres Nephrology Section Hospital Universitario de Canarias University of La Laguna Tenerife, Canary Islands, Spain.
Does RAS blockade improve outcomes after kidney transplantation? Armando Torres, La Laguna, Spain Chairs: Hans De Fijter, Leiden, The Netherlands Armando Torres, La Laguna, Spain Prof. Armando Torres Nephrology
More informationINFLUENCE OF LOW PROTEIN DIET IN IMPROVING ANEMIA TREATED WITH ERYTHROPOETIN
INFLUENCE OF LOW PROTEIN DIET IN IMPROVING ANEMIA TREATED WITH ERYTHROPOETIN, Idrizi A, Barbullushi M, Gjyzari A, Duraku A Department of Nephrology, University Hospital Center, Tirana, Albania Introduction
More informationAcute renal failure Definition and detection
Acute renal failure Definition and detection Pierre Delanaye, MD, PhD Nephrology, Dialysis, Transplantation CHU Sart Tilman University of Liège BELGIUM Definition Acute Renal Failure Acute Kidney Injury
More informationSERVICE SPECIFICATION 6 Conservative Management & End of Life Care
SERVICE SPECIFICATION 6 Conservative Management & End of Life Care Table of Contents Page 1 Key Messages 2 2 Introduction & Background 2 3 Relevant Guidelines & Standards 2 4 Scope of Service 3 5 Interdependencies
More informationUnderstanding Acute Kidney Injury and Its Impact
Understanding Acute Kidney Injury and Its Impact Recorded on: March 7, 2013 Chi-Yuan Hsu, M.D., M.S. Chief of the Division of Nephrology, UCSF Department of Medicine UCSF Medical Center Raymond Hsu, M.D.
More informationTolvaptan (Jinarc ) for Adult Polycystic Kidney Disease (ADPKD)
Oxford Kidney Unit Tolvaptan (Jinarc ) for Adult Polycystic Kidney Disease (ADPKD) Information for patients What is tolvaptan? Tolvaptan (Jinarc ) is the first drug specifically for the treatment of adult
More informationNew global report highlights silent epidemic of kidney disease and neglect of treatment and prevention in all countries
New global report highlights silent epidemic of kidney disease and neglect of treatment and prevention in all countries An estimated 1 in 10 people worldwide have chronic kidney disease **Embargo: 18:00H
More informationRenal Replacement Therapy - Indication and Follow up
Renal Replacement Therapy - Indication and Follow up Prof Brigadier General Mamun Mostafi FCPS, FRCP Chief Physician Combined Military Hospital Dhaka Bangladesh Primary Functions of the Kidney Removal
More informationDr. Liliana Garneata Assistant Professor of Nephrology Dr Carol Davila Teaching Hospital of Nephrology, Bucharest, Romania
Dr. Liliana Garneata Assistant Professor of Nephrology Dr Carol Davila Teaching Hospital of Nephrology, Bucharest, Romania Nutritional management of CKD: Key-role of ketoanalogues with low protein diets
More informationInformation for patients with kidney disease attending the Low Clearance Clinic
Information for patients with kidney disease attending the Low Clearance Clinic Why am I attending this Clinic? Your kidneys are not working effectively. This means they cannot do their usual jobs such
More informationThe New Kidney Allocation System: What You Need to Know. Quality Insights Renal Network 3 Annual Meeting October 2, 2014
The New Kidney Allocation System: What You Need to Know Quality Insights Renal Network 3 Annual Meeting October 2, 2014 Pre Dialysis Era Dialysis Status in USA 500,000 patients on dialysis in 2013 100,000
More informationKaty Trinkley PharmD, BCACP Tiffany Goldberg Pharm D Candidate Katie Heist MD
Katy Trinkley PharmD, BCACP Tiffany Goldberg Pharm D Candidate Katie Heist MD Metformin: Only oral diabetes medication with proven benefits on cardiovascular morbidity and mortality Inexpensive medication
More informationSection Questions Answers
Section Questions Answers Guide to CKD Screening and Evaluation -Alec Otteman, MD Delaying Progression - Paul Drawz, MD, MHS, MS 1. Modifiable risk factors for CKD include: a. Diabetes b. Hypertension
More informationProf. Sandrine Florquin Department of Pathology Academic Medical Center University of Amsterdam Amsterdam, The Netherlands. Slide 1.
Interleukin 17 in renal biopsies as risk factor for progression Sandrine Florquin, Amsterdam, The Netherlands Chairs: Mohamed R. Daha, Leiden, The Netherlands Pierre Ronco, Paris, France Prof. Sandrine
More informationNational Chronic Kidney Disease Audit
National Chronic Kidney Disease Audit // National Report: Part 2 December 2017 Commissioned by: Delivered by: // Foreword by Fiona Loud And if, as part of good, patient-centred care, a record of your condition(s),
More informationSAMPLE. Chronic Kidney Disease, Evidence-Based Practice, and the Nutrition Care Process. Chapter 1
Chapter 1 Chronic Kidney Disease, Evidence-Based Practice, and the Nutrition Care Process This guide follows the steps of the Nutrition Care Process (NCP) nutrition assessment, nutrition diagnosis, nutrition
More informationTHE CONSERVATIVE CARE PATHWAY
THE CONSERVATIVE CARE PATHWAY Dr. Gaylene Hargrove Sept. 19, 2015 Island Health Renal Program End of Life Conference Learning Objectives Describe and discuss what defines conservative care. Identify key
More informationThe UK Renal Registry collects national data about the causes and treatment of kidney failure.
1 Kidney failure is a serious condition. Many kidney patients receive some form of renal replacement therapy (RRT) such as dialysis. The UK Renal Registry collects national data about the causes and treatment
More informationSeptember 28, 2013 Jennifer Butler, RN, CCTC
How To Get Listed for Kidney Transplant September 28, 2013 Jennifer Butler, RN, CCTC Objectives What kidney failure is 3 major forms of treatment Kidney transplant evaluation Kidney transplant List Functions
More informationGadolinium Based Contrast Agent Recommendations (Revised 06/07/2018)
Gadolinium Based Contrast Agent Recommendations (Revised 06/07/2018) Introduction: Nephrogenic systemic fibrosis is the only known adverse health effect related to gadoliniumbased contrast agents (GBCAs).
More informationSection 4 Decision-making
Decision-making : Decision-making Summary Conversations about treatments Participants were asked to describe the conversation that they had with the clinician about treatment at diagnosis. The most common
More informationHow the UK Renal Registry has improved the lives of renal patients
How the UK Renal Registry has improved the lives of renal patients [is improving and will improve] Dr Fergus Caskey Medical Director of the UK Renal Registry NKF Annual Conference, Reading, 10th October
More informationGeriatric Nephrology. Murtener Tage
Geriatric Nephrology Murtener Tage 2014 Isabelle.Binet@kssg.ch www.nierenstiftung.ch Plan Geriatric nephrology The elderly with CKD The elderly on dialysis The elderly in transplantation Plan Geriatric
More informationProf. Michael Joannidis Medical Intensive Care and Emergency Unit Department of Internal Medicine Medical University Innsbruck Innsbruck, Austria
1 di 27 Prevention of AKI: experimental promises and clinical realities Michael Joannidis, Innsbruck, Austria Chairs:Norbert Lameire, Ghent, Belgium Gert Mayer, Innsbruck, Austria Prof. Michael Joannidis
More informationHave you seen a patient like Elaine *?
(linagliptin) 5mg tablets Have you seen a patient like Elaine *? *Hypothetical patient profile Elaine * : 60 years old Housewife *Hypothetical patient profile ELAINE*: T2D Patient with early signs of kidney
More informationOffice Management of Reduced GFR Practical advice for the management of CKD
Office Management of Reduced GFR Practical advice for the management of CKD CKD Online Education CME for Primary Care April 27, 2016 Monica Beaulieu, MD FRCPC MHA CHAIR PROVINCIAL KIDNEY CARE COMMITTEE
More informationProblems with Outliers in Breath Alcohol Testing
Problems with Outliers in Breath Alcohol Testing Jo c h e n W ilske Blood alcohol concentration (BAC) and impairment o f driving skills are related so closely, that statutory drink-drive limits are accepted
More informationModifying Drug Dosing for Patients with Renal Insufficiency
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/focus-on-pharmacy/modifying-drug-dosing-for-patients-with-renalinsufficiency/3427/
More informationOutcomes of dialysis in the elderly. DNT March 2011 Dr Céline Foote
Outcomes of dialysis in the elderly DNT March 2011 Dr Céline Foote Increasing number of elderly patients on renal replacement therapy 500 500 Patients per million 400 300 200 100 400 300 200 100 TOTAL
More informationNephrology referral - Does my patient need it? Disclosure
Nephrology referral - Does my patient need it? Sophia Chou, MD MSc March 10, 2018 Faculty: Sophia Chou Disclosure Relationships with commercial interest: None Potential conflict of interest: None 1 Objectives
More informationWhatever You Do, DON'T Make These 5 Weight Loss MISTAKES
Whatever You Do, DON'T Make These 5 Weight Loss MISTAKES BY: EXIT MAN (Sohil Farahmand) Mistake #1: Trying To Introduce Too Many Habits At Once When you're motivated you're motivated. When you want to
More informationAnticoagulation, atrial fibrillation in elderly patients with chronic kidney disease
Anticoagulation, atrial fibrillation in elderly patients with chronic kidney disease Zbigniew Heleniak M.D. Ph.D. Department of Nephrology, Transplantology and Internal Medicine Medical University of Gdansk
More informationRenal function vs chemotherapy dosing
Renal function vs chemotherapy dosing Jenny Casanova Senior Clinical Pharmacist Repatriation General Hospital Daw Park 1 Methods of estimating renal function Cockcroft-Gault (1976) C-G using ideal vs actual
More informationEast London Community Kidney Service
East London Community Kidney Service Sally Hull, Neil Ashman, Sec Hoong, Nicola Thomas, Helen Rainey April 2017 Haemodialysis/million population What is the Problem? Fast rising ESRD rates in East London
More informationTolvaptan for treating autosomal dominant polycystic kidney disease
in collaboration with: ERRATUM TO Tolvaptan for treating autosomal dominant polycystic kidney disease 1. The word ********* has been marked as commercial in confidence. a. Section 1.4 (page 13): Hence,
More informationegfr 34 ml/min egfr 130 ml/min Am J Kidney Dis 2002;39(suppl 1):S17-S31
Update on Renal Therapeutics Caroline Ashley Lead Pharmacist Renal Services UCL Centre for Nephrology, Royal Free Hospital, London Kongress für Arzneimittelinformation January 2011 What are we going to
More informationHave you seen a patient like Carol *?
(linagliptin) 5mg tablets Have you seen a patient like Carol *? *Hypothetical patient profile Carol * : 70 years old Retired schoolteacher *Hypothetical patient profile CAROL*: T2D patient with moderate
More informationMOLECULAR PREDICTORS OF OUTCOME Ondrej Viklicky, Prague, Czech Republic. Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy
MOLECULAR PREDICTORS OF OUTCOME Ondrej Viklicky, Prague, Czech Republic Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy Prof Ondrej Viklicky Department of Nephrology Transplant
More informationANAEMIA MANAGEMENT: HOW AND WHY DOES ERBP DIFFER FROM KDIGO Francesco Locatelli, Lecco, Italy
ANAEMIA MANAGEMENT: HOW AND WHY DOES ERBP DIFFER FROM KDIGO Francesco Locatelli, Lecco, Italy Chair: Kai- Uwe Eckardt, Erlangen, Germany Pierre- Yves Martin, Geneva, Switzerland Prof. Francesco Locatelli
More informationThe EQUAL study: a European study in chronic kidney disease stage 4 patients
Nephrol Dial Transplant (2012) 27 (Supple 3): iii27 iii31 doi: 10.1093/ndt/gfs277 Advance Access publication 4 July 2012 Editorial Review The EQUAL study: a European study in chronic kidney disease stage
More informationRenal Failure Update in Treatment Part 1. DANIEL WALTON, DO, FACP,FACOI,FASN PARTNER, AKDHC, LLC PHOENIX AZ (602)
Renal Failure Update in Treatment Part 1 DANIEL WALTON, DO, FACP,FACOI,FASN PARTNER, AKDHC, LLC PHOENIX AZ (602) 263 5446 dwalton@akdhc.com DISCLOSURES NONE OFF LABEL USE POSSIBLY LEARNING OBJECTIVES USE
More informationElevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC
Elevation of Serum Creatinine: When to Screen, When to Refer Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC Presented at the University of Calgary s CME and Professional Development 2006-2007
More informationWhat Happened? 3/20/2017. Changing Lives and Making a Difference: Home Hemodialysis Stories. Brigitte Schiller, MD, FACP, FASN
Changing Lives and Making a Difference: Home Hemodialysis Stories Brigitte Schiller, MD, FACP, FASN Chief Medical Officer Satellite Healthcare What Happened? We started building centers We started peritoneal
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationLIVE KIDNEY DONOR RISK PREDICTION ; NEW PARADIGM, NEW CALCULATORS PEDRAM AHMADPOOR MD
LIVE KIDNEY DONOR RISK PREDICTION ; NEW PARADIGM, NEW CALCULATORS PEDRAM AHMADPOOR MD Outline: PART 1 : Update on safety of nephrectomy for living donor candidate PART 2 : Latest guideline recommendation
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More informationDiabetes and Kidney Disease. Kris Bentley Renal Nurse practitioner 2018
Diabetes and Kidney Disease Kris Bentley Renal Nurse practitioner 2018 Aims Develop an understanding of Chronic Kidney Disease Understand how diabetes impacts on your kidneys Be able to recognise the risk
More informationPatient Description and Diagnosis: Sarah Jones is a 50-year-old female, 5 4, 131
Julia Kaesberg Counseling Session KNH 413 February 27 th, 2014 Patient Description and Diagnosis: Sarah Jones is a 50-year-old female, 5 4, 131 pounds and her usual body weight is 125 pounds. Her %UBW
More informationSpecial Challenges and Co-Morbidities
Special Challenges and Co-Morbidities Renal Disease/ Hypertension/ Diabetes in African-Americans M. Keith Rawlings, MD Medical Director Peabody Health Center AIDS Arms, Inc Dallas, TX Chair, Internal Medicine
More informationCost-effectiveness of tolvaptan (Jinarc ) for the treatment of autosomal dominant polycystic kidney disease (ADPKD)
Cost-effectiveness of tolvaptan (Jinarc ) for the treatment of autosomal dominant polycystic kidney disease (ADPKD) The NCPE has issued a recommendation regarding the cost-effectiveness of tolvaptan (Jinarc
More informationChronic renal failure
Chronic renal failure Dr. Alexander Woywodt Consultant Physician and Nephrologist / Hon. Senior Lecturer Lancashire Teaching Hospitals NHS Foundation Trust Fleetwood 23rd June 2009 Menu Epidemiology &
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationGuidelines for the psychological management of chronic kidney disease patients (for the Psychologist)
Indian J Nephrol 2005;15, Supplement 1: S103-S108 S 103 Guidelines for the psychological management of chronic kidney disease patients (for the Psychologist) Introduction With increasing levels of sophistication
More informationEpidemiology of CKD in Children
Epidemiology of CKD in Children Ali Düzova, M.D. Hacettepe University Faculty of Medicine Pediatric Nephrology and Rheumatology Unit Ankara CKD Course 03 June 2011, İstanbul Aim & Plan Causes of CKD in
More informationAustralian adults => 25 yrs of age. Australia, Australian Health sector
CHAPTER 4-CKD GUIDELINE 4.1. THE INFLUENCE OF GFR, AGE, GENDER, ETHNICITY AND PROTEINURIA ON PATIENT OUTCOMES Q: At what level of GFR are patient outcomes significantly affected? Does this change with
More informationDr. Mehmet Kanbay Department of Medicine Division of Nephrology Istanbul Medeniyet University School of Medicine Istanbul, Turkey.
The uric acid dilemma: causal risk factor for hypertension and CKD or mere bystander? Mehmet Kanbay, Istanbul, Turkey Chairs: Anton H. van den Meiracker, Rotterdam, The Netherlands Claudia R.C. Van Roeyen,
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More information